Hyderabad (Telangana) [India], August 14 (ANI): Hyderabad-based pharmaceuticals and biologics firm Biological E. Limited (BE) on Thursday entered into an agreement with Janssen Pharmaceutica NV, part of pharma major Johnson & Johnson, for the creation and enhancement of manufacturing capacities for Johnson & Johnson's COVID-19 vaccine candidate.

The vaccine candidate of Johnson and Johnson currently undergoing phase 1/2a clinical trials, said the Hyderabad-based vaccine maker in a press statement.

Also Read | Independence Day 2020: From 1857 Revolt to Quit India Movement, Timeline of Major Events in The Freedom Struggle.

"We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the COVID-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration," said Mahima Datla, Managing Director of BE.

"We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson's commitment to global access for its COVID-19 vaccine," said Narender Dev Mantena, Director of BioE Holdings Inc., who heads BE's novel vaccine initiative.

Also Read | Odisha: School and Mass Education Department Issues Guidelines for Independence Day 2020 Celebration in Schools: Live Breaking News Headlines & Coronavirus Updates on August 13, 2020.

The WHO had declared COVID-19, caused by the novel coronavirus SARS-CoV-2, a pandemic in March. (ANI)

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)